Century Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Century Therapeutics, Inc.

Century Therapeutics, Inc. (ticker: IPSC) is a U.S.-listed biotechnology company trading on NASDAQ in the United States. For French-, Belgian- and Swiss-based investors, this is a classic development-stage cell therapy story: a science-driven biotech with significant platform optionality, but whose investment case still depends on clinical execution, regulatory progress, financing discipline and eventual proof that its engineered products can translate into durable therapeutic benefit. Century was founded in 2018 by Versant Ventures and launched in 2019 with an initial $250 million financing. The company is headquartered in Philadelphia, Pennsylvania, and maintains operating footprints in New Jersey and Boston, with an additional innovation presence in Seattle. Its strategic identity is built around an allogeneic induced pluripotent stem cell (iPSC) platform combined with immune-evasion engineering. In practical terms, Century aims to create “off-the-shelf” cell therapies that could be manufactured at scale, potentially improving access, consistency and affordability versus more complex autologous cell therapy approaches. The core business is the development of iPSC-derived therapies for cancer and autoimmune disease. Century’s platform integrates gene editing, protein engineering and manufacturing capabilities to generate differentiated product candidates under its Allo-Evasion™ approach. The most important pipeline programs currently highlighted by management are CNTY-813, an islet replacement therapy for type 1 diabetes with functional-cure potential, and CNTY-308, a CD19-targeted CAR-iT program being advanced for B-cell mediated autoimmune diseases and with relevance to oncology applications. In 2025, the company re-prioritized its preclinical pipeline to focus resources on a smaller number of programs considered the most transformational. From a competitive standpoint, Century operates in a crowded and highly capital-intensive field that includes cell-therapy developers, iPSC platform companies and other allogeneic immunotherapy players. Its potential differentiation lies in combining a scalable iPSC manufacturing model with engineered immune evasion and a focus on high-unmet-need indications. That said, the company remains exposed to the usual biotech risks: clinical failure, regulatory delays, manufacturing complexity and the need to continually secure capital. Recent developments are material. In January 2026, Century completed an oversubscribed $135 million private placement, extending cash runway into 1Q 2029. In May 2026, the company reported that CNTY-813 remained on track for an IND submission in 4Q 2026, with initial clinical data expected in 2H 2027, while CNTY-308 was also advancing toward clinic in 2026. These updates, together with the company’s ongoing SEC Form 4 insider transaction filings, make IPSC a name that investors typically monitor for catalyst-driven volatility rather than current operating profitability.